CHRONIC MYELOGENOUS LEUKEMIA ON TYROSINE KINASE INHIBITORS-
HEMATOLOGICAL CHANGES AND CORRELATION WITH EUROPEAN LEUKEMIA
POSTER 18
NETWORK RESPONSE CRITERIA
Shano Naseem1, Karthik Bommannan2, Neelam Varma3, Pankaj Malhotra4 and Subhash Varma5
(1)Additional Professor, Department of Hematology, PGIMER, Chandigarh, India
(2)DM Hematopathology Fellow, Department of Hematology, PGIMER, Chandigarh, India
(3)Professor & Head, Department of Hematology, PGIMER, Chandigarh, India
(4)Adult Clinical Hematology Unit, Department of Internal Medicine, PGIMER, Chandigarh, India
(5)Professor & Head, Department of Internal Medicine, PGIMER, Chandigarh, India
Introduction-Chronic myeloid leukemia (CML) patients receive tyrosine kinase inhibitor (TKI)
therapy for long duration. In this study we analyzed hematological changes and compared
with hematological and cytogenetic response in 542 CML patients with a follow up period of
84 months.
Methodology-CML patients on TKI therapy with minimum follow up of 6 months were
enrolled over a period of 8 years. Response was evaluated as per European Leukemia Network
guidelines.
Results- Normalization of platelet count, total leucocyte count, marrow cellularity and
granulocytic hyperplasia occurred by 3rd month of TKI therapy. Cytopenias were invariably
seen at all follow-up time points, with thrombocytopenia, being most common therapy
induced cytopenia. Marrow hypocellularity and lymphoid nodules were seen in nearly 20%
patients during TKI therapy. Marrow hypercellularity was higher in ‘Not in complete
hematological response (NCHR) patients than those in CHR.
Conclusion- Peripheral blood and bone marrow remain normal in majority of patients (60-
90%). TKI induced changes observed over different follow-up intervals include- cytopenia,
marrow hypocellularity and lymphoid nodules. Only, bone marrow hypercellularity was
significantly different for CHR and NCHR. No peripheral blood and bone marrow parameter
was different in optimal and non-optimal cytogenetic responders.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES